Trials / Conditions / Stage IV Uveal Melanoma AJCC v7

Stage IV Uveal Melanoma AJCC v7

10 registered clinical trials studyying Stage IV Uveal Melanoma AJCC v7.

Status	Trial	Sponsor	Phase
Completed	Ipilimumab and Nivolumab With Immunoembolization in Treating Participants With Metastatic Uveal Melanoma in th NCT03472586	Sidney Kimmel Comprehensive Cancer Center at Thomas Jefferson University	Phase 2
Withdrawn	Glembatumumab Vedotin, Nivolumab, and Ipilimumab in Treating Patients With Advanced Metastatic Solid Tumors Th NCT03326258	National Cancer Institute (NCI)	Phase 1 / Phase 2
Completed	Neoadjuvant and Adjuvant Checkpoint Blockade NCT02519322	M.D. Anderson Cancer Center	Phase 2
Completed	Glembatumumab Vedotin in Treating Patients With Metastatic or Locally Recurrent Uveal Melanoma NCT02363283	National Cancer Institute (NCI)	Phase 2
Active Not Recruiting	Trametinib With or Without GSK2141795 in Treating Patients With Metastatic Uveal Melanoma NCT01979523	National Cancer Institute (NCI)	Phase 2
Completed	Nab-Paclitaxel and Bevacizumab or Ipilimumab as First-Line Therapy in Treating Patients With Stage IV Melanoma NCT02158520	Academic and Community Cancer Research United	Phase 2
Completed	Cabozantinib-S-Malate Compared With Temozolomide or Dacarbazine in Treating Patients With Metastatic Melanoma NCT01835145	National Cancer Institute (NCI)	Phase 2
Completed	Nivolumab and Ipilimumab in Treating Patients With Metastatic Uveal Melanoma NCT01585194	M.D. Anderson Cancer Center	Phase 2
Active Not Recruiting	Vorinostat in Treating Patients With Metastatic Melanoma of the Eye NCT01587352	National Cancer Institute (NCI)	Phase 2
Completed	Sargramostim, Vaccine Therapy, or Sargramostim and Vaccine Therapy in Preventing Disease Recurrence in Patient NCT01989572	National Cancer Institute (NCI)	Phase 3